Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,000,000 shares, a drop of 7.4% from the January 15th total of 2,160,000 shares. Based on an average daily trading volume, of 785,400 shares, the short-interest ratio is currently 2.5 days.

Wall Street Analyst Weigh In

CRL has been the subject of several analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday. William Blair lowered shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. TD Cowen raised their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. Robert W. Baird decreased their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research note on Thursday. Finally, Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $195.71.

Charles River Laboratories International Price Performance

NYSE:CRL traded up $0.86 during trading hours on Friday, hitting $163.11. The stock had a trading volume of 1,211,306 shares, compared to its average volume of 1,060,332. The company has a 50 day simple moving average of $173.39 and a two-hundred day simple moving average of $188.81. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International has a one year low of $150.79 and a one year high of $275.00. The firm has a market capitalization of $8.34 billion, a price-to-earnings ratio of 1,087.39, a P/E/G ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period last year, the firm earned $2.46 EPS. The business's quarterly revenue was down 1.1% compared to the same quarter last year. Research analysts forecast that Charles River Laboratories International will post 9.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CRL. Versant Capital Management Inc lifted its holdings in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after acquiring an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. lifted its holdings in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after acquiring an additional 173 shares during the last quarter. Optiver Holding B.V. bought a new stake in shares of Charles River Laboratories International during the 4th quarter worth $37,000. Finally, GeoWealth Management LLC lifted its holdings in shares of Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after acquiring an additional 190 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).